Incidence and predictors of adverse events after dual antiplatelet therapy (DAPT) cessation in patients treated with thin stents (<100 microns) in unprotected left main (ULM) or coronary bifurcation remain undefined. All consecutive patients presenting with a critical lesion of an ULM or involving a main coronary bifurcation who were treated with very thin strut stents were included. MACE (a composite end point of cardiovascular death, myocardial infarction [MI], target lesion revascularization [TLR], and stent thrombosis [ST]) was the primary endpoint, whereas target vessel revascularization (TVR) was the secondary endpoint, with particular attention to type and occurrence of ST and occurrence of ST, CV death, and MI during DAPT or after DAPT discontinuation. All analyses were performed according to length of DAPT dividing the patients in 3 groups: Short DAPT (3-months), intermediate DAPT (3 to 12 months), and long DAPT (12-months). A total of 117 patients were discharged with an indication for DAPT ≤3 months (median 1: 1 to 2.5), 200 for DAPT between 3 and 12 months (median 8: 7 to 10), and 1,958 with 12 months DAPT. After 12.8 months (8 to 20), MACE was significantly higher in the 3-month group compared with 3 to 12 and 12-month groups (9.4% vs 4.0% vs 7.2%, p ≤0.001), mainly driven by MI (4.4% vs 1.5% vs 3%, p ≤0.001) and overall ST (4.3% vs 1.5% vs 1.8%, p ≤0.001). Independent predictors of MACE were low GFR and a 2 stent strategy. Independent predictors of ST were DAPT duration <3 months and the use of a 2-stent strategy. In conclusion, even stents with very thin strut when implanted in real-life ULM or coronary bifurcation patients discharged with short DAPT have a relevant risk of ST, which remains high although not significant after DAPT cessation.

Incidence of adverse events at 3 months versus at 12 months after dual antiplatelet therapy cessation in patients treated with thin stents with unprotected left main or coronary bifurcations / D'Ascenzo, Fabrizio; Barbero, Umberto; Abdirashid, Mohamed; Trabattoni, Daniela; Boccuzzi, Giacomo; Ryan, Nicola; Quadri, Giorgio; Capodanno, Davide; Venuti, Giuseppe; Muscoli, Saverio; Tomassini, Francesco; Autelli, Michele; Montabone, Andrea; Wojakowski, Wojciech; Rognoni, Andrea; Gallo, Diego; Parma, Radoslaw; De Luca, Leonardo; Figini, Filippo; Mitomo, Satoru; Montefusco, Antonio; Mattesini, Alessio; Wańha, Wojciech; Protasiewicz, Marcin; Smolka, Grzegorz; Huczek, Zenon; Rolfo, Cristina; Cortese, Bernardo; Chieffo, Alaide; Kuliczowki, Wiktor; Nuñez-Gil, Ivan; Morbiducci, Umberto; Ugo, Fabrizio; Marengo, Giorgio; Iannaccone, Mario; Cerrato, Enrico; di Mario, Carlo; Moretti, Claudio; D'Amico, Maurizio; Varbella, Ferdinando; Lüscher, Thomas; Sheiban, Imad; Escaned, Javier; Romeo, Francesco; Rinaldi, Mauro; De Ferrari, Gaetano Maria; Helft, Gerard.. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - ELETTRONICO. - 125:4(2020), pp. 491-499. [10.1016/j.amjcard.2019.10.058]

Incidence of adverse events at 3 months versus at 12 months after dual antiplatelet therapy cessation in patients treated with thin stents with unprotected left main or coronary bifurcations

D'Ascenzo, Fabrizio;Gallo, Diego;Morbiducci, Umberto;Rinaldi, Mauro;
2020

Abstract

Incidence and predictors of adverse events after dual antiplatelet therapy (DAPT) cessation in patients treated with thin stents (<100 microns) in unprotected left main (ULM) or coronary bifurcation remain undefined. All consecutive patients presenting with a critical lesion of an ULM or involving a main coronary bifurcation who were treated with very thin strut stents were included. MACE (a composite end point of cardiovascular death, myocardial infarction [MI], target lesion revascularization [TLR], and stent thrombosis [ST]) was the primary endpoint, whereas target vessel revascularization (TVR) was the secondary endpoint, with particular attention to type and occurrence of ST and occurrence of ST, CV death, and MI during DAPT or after DAPT discontinuation. All analyses were performed according to length of DAPT dividing the patients in 3 groups: Short DAPT (3-months), intermediate DAPT (3 to 12 months), and long DAPT (12-months). A total of 117 patients were discharged with an indication for DAPT ≤3 months (median 1: 1 to 2.5), 200 for DAPT between 3 and 12 months (median 8: 7 to 10), and 1,958 with 12 months DAPT. After 12.8 months (8 to 20), MACE was significantly higher in the 3-month group compared with 3 to 12 and 12-month groups (9.4% vs 4.0% vs 7.2%, p ≤0.001), mainly driven by MI (4.4% vs 1.5% vs 3%, p ≤0.001) and overall ST (4.3% vs 1.5% vs 1.8%, p ≤0.001). Independent predictors of MACE were low GFR and a 2 stent strategy. Independent predictors of ST were DAPT duration <3 months and the use of a 2-stent strategy. In conclusion, even stents with very thin strut when implanted in real-life ULM or coronary bifurcation patients discharged with short DAPT have a relevant risk of ST, which remains high although not significant after DAPT cessation.
File in questo prodotto:
File Dimensione Formato  
Incidence of Adverse Events ....pdf

non disponibili

Tipologia: 2a Post-print versione editoriale / Version of Record
Licenza: Non Pubblico - Accesso privato/ristretto
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
AJC_2019DAscenzo_postprint.pdf

Open Access dal 24/11/2020

Tipologia: 2. Post-print / Author's Accepted Manuscript
Licenza: Creative commons
Dimensione 2.72 MB
Formato Adobe PDF
2.72 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2842974